APOE genotyping in Alzheimer's disease
In the therapy of Alzheimer’s disease with new active substances (e.g. lecanemab, donanemab), patients with two copies of the apolipoprotein E (APOE) allele ε4 have an increased risk of potentially life-threatening side effects. APOE genotyping with the EURORealTime APOE prior to therapy provides clarity.
more